

Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.

The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

Rejected

General description

INN

Emtricitabine + rilpivirine + tenofovir

ATC codes

[J05AR08](#)

Medicine type

Chemical agent

EML status history

Application rejected in 2015 ([TRS 994](#)) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Wikipedia

[Emtricitabine + rilpivirine + tenofovir disoproxil fumarate](#)

DrugBank

[Emtricitabine](#),

[Rilpivirine](#),

[Tenofovir disoproxil fumarate \(Tenofovir disoproxil\)](#)

Recommendations

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)